Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B ROTHMAN

Showing results (441-450 of 606) with videos related to

Pageof 61
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switchingMasaki Kashiwada, Deborah M Levy, Lisa McKeag, et al.
Synapse (New York, N.Y.)|September 30, 2003
High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrainRichard B Rothman, Subramaniam Jayanthi, Xiaoying Wang, et al.
Synapse (New York, N.Y.)|November 9, 2000
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotoninR B Rothman, M H Baumann, C M Dersch, et al.
European Journal of Medicinal Chemistry|February 21, 2012
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activityMalliga R Iyer, Yong Sok Lee, Jeffrey R Deschamps, et al.
Neurochemical Research|September 1, 1994
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor bindingQ Ni, H Xu, J S Partilla, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 7, 2009
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinilDorota Zolkowska, Raka Jain, Richard B Rothman, et al.
Experimental and Clinical Psychopharmacology|May 7, 2014
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeysMatthew L Banks, Clayton T Bauer, Bruce E Blough, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinansSubramaniam Ananthan, Hollis S Kezar, Surendra K Saini, et al.
European Journal of Pharmacology|May 13, 1986
Morphine tolerance increases mu-noncompetitive delta binding sitesR B Rothman, J A Danks, A E Jacobson, et al.
Bioorganic & Medicinal Chemistry|December 17, 2009
Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-olsMalliga R Iyer, Yong Sok Lee, Jeffrey R Deschamps, et al.
Pageof 61

Showing results (441-450 of 606) with videos related to

Sort By:
Pageof 61
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switchingMasaki Kashiwada, Deborah M Levy, Lisa McKeag, et al.
Synapse (New York, N.Y.)|September 30, 2003
High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrainRichard B Rothman, Subramaniam Jayanthi, Xiaoying Wang, et al.
Synapse (New York, N.Y.)|November 9, 2000
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotoninR B Rothman, M H Baumann, C M Dersch, et al.
European Journal of Medicinal Chemistry|February 21, 2012
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activityMalliga R Iyer, Yong Sok Lee, Jeffrey R Deschamps, et al.
Neurochemical Research|September 1, 1994
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor bindingQ Ni, H Xu, J S Partilla, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 7, 2009
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinilDorota Zolkowska, Raka Jain, Richard B Rothman, et al.
Experimental and Clinical Psychopharmacology|May 7, 2014
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeysMatthew L Banks, Clayton T Bauer, Bruce E Blough, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinansSubramaniam Ananthan, Hollis S Kezar, Surendra K Saini, et al.
European Journal of Pharmacology|May 13, 1986
Morphine tolerance increases mu-noncompetitive delta binding sitesR B Rothman, J A Danks, A E Jacobson, et al.
Bioorganic & Medicinal Chemistry|December 17, 2009
Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-olsMalliga R Iyer, Yong Sok Lee, Jeffrey R Deschamps, et al.
Pageof 61